Skip to content
  • ABOUT US
    • Overview
    • Our Directors and Team
  • News
  • Medical Cannabis
    • About Medicinal Cannabis
    • About the Dolce NTI164 strain
  • MENTE TECHNOLOGY
  • INVESTOR CENTRE
    • ASX Announcements
    • FAQ’s
    • Annual Reports
    • Corporate Governance
  • CONTACT
Menu
  • ABOUT US
    • Overview
    • Our Directors and Team
  • News
  • Medical Cannabis
    • About Medicinal Cannabis
    • About the Dolce NTI164 strain
  • MENTE TECHNOLOGY
  • INVESTOR CENTRE
    • ASX Announcements
    • FAQ’s
    • Annual Reports
    • Corporate Governance
  • CONTACT
intbannerone

news

6th Oct 2021

Bioshares: Neurotech International Phase I/II Autism Results Due

4th Sep 2021

Simply Wall Street: Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

18th Aug 2021

The Market Herald: From Backstreet to Highstreet: How Cannabis Has Entered the Mainstream

6th May 2021

Stockhead: Neurotech just started world’s first THC-less cannabis study in autistic children

5th May 2021

FinFeed: Neurotech embarks on ground-breaking ASD trials

11th Mar 2021

Hemp Gazette: Australia’s Neurotech Inks Cannabis Cultivation Partnership

3rd Jul 2020

The Market Herald: Neurotech International (ASX:NTI) secures option to Dolce Cann Global’s cannabis strains

Neurotech International Limited
Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

  • ABOUT US
  • INVESTOR CENTRE
  • ASX Announcements
  • TECHNOLOGY
  • Annual Reports
Menu
  • ABOUT US
  • INVESTOR CENTRE
  • ASX Announcements
  • TECHNOLOGY
  • Annual Reports
  • Our Team
  • Our Directors and Team
  • CONTACT
  • PRIVACY POLICY
  • TERMS & CONDITIONS
Menu
  • Our Team
  • Our Directors and Team
  • CONTACT
  • PRIVACY POLICY
  • TERMS & CONDITIONS

© Copyright 2021.
Neurotech International Limited